Journal: BMC Cancer

Article Title: The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer

doi: 10.1186/s12885-019-5422-x

Figure Lengend Snippet: Proteogenomics profiling of the expression of complement and complement-related components in patients with lung cancer

Article Snippet: Antibodies against C5 (1:1000; ab66850), CFH (1:5000, ab36134) and C9 (1:1000, ab173302) were purchased from Abcam (Cambridge, MA); Antibodies against C4BPA (1:1000, 11,819–1-AP), C4BPB (1:1000, 15,837–1-AP), CFB (1:1000, 10,170–1-AP), and goat anti-rabbit, goat anti-mouse and rabbit anti-goat secondary antibodies were purchased from Proteintech Group, Inc., Wuhan Sanying (Wuhan, China).

Techniques: Expressing, Membrane

Journal: BMC Cancer

Article Title: The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer

doi: 10.1186/s12885-019-5422-x

Figure Lengend Snippet: Levels of complement components in lung cancer tissues (LC) and paracancerous tissues (PC) from two patients. Lower concentrations of complement components (C3, C4, C5, C4BPA, C4BPB, C6, C7, C9, CFH and CFI) were observed in LC than in PC at the mRNA ( a ) and protein ( b ) levels. The mRNA levels of complement components C3, C4, C5, C4BPA, C4BPB, C6, C7, C9, CFH and CFI were decreased 6.4-, 2-, 11-, 8.6-, 64-, 4.5-, 5.5-, 7-, 9- and 13.5-fold in LC, respectively ( a ). α-Tubulin was used as the loading control ( b ). Data are presented as the means ± SD ( n = 3). * p < 0.05, ** p < 0.01

Article Snippet: Antibodies against C5 (1:1000; ab66850), CFH (1:5000, ab36134) and C9 (1:1000, ab173302) were purchased from Abcam (Cambridge, MA); Antibodies against C4BPA (1:1000, 11,819–1-AP), C4BPB (1:1000, 15,837–1-AP), CFB (1:1000, 10,170–1-AP), and goat anti-rabbit, goat anti-mouse and rabbit anti-goat secondary antibodies were purchased from Proteintech Group, Inc., Wuhan Sanying (Wuhan, China).

Techniques: Control

Journal: BMC Cancer

Article Title: The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer

doi: 10.1186/s12885-019-5422-x

Figure Lengend Snippet: Expression profiles of complement and complement-related components in serum and cancer tissues from patients with lung cancer. X-axis: Numbers 1 to 63 represent C1s, C1r, C1QA, C1QB, C1QC, C2, C4d/C4, MASP1, CFD, CFP, CFB, C3, C5, C6, C7, C8A, C8B, C8G, C9, C1NH, C1QBP, CFI, C4BPA, C4BPB, CFH, CLU , VTN , VWF , SERPINA1 , SERPINA3 , CD55, CD59, CD44, CD46, CD35/CR1, CD21/CR2, CD11b/CR3, CD11c/CR4, CD18/CR3, MRC1, C3AR1, C5AR1, C3bR, C1QR1, APOA1 , APOA2 , APOA4 , APOB , APOC1 , APOC2 , APOC3 , APOD , APOE , APOL3, A2M , SERPINB1 , SERPINB2 , SERPINB5 , SERPIND1 , SERPINF1 , SERPINH1, SERPINI1 and SERBP1 , respectively. Complement-related components were indicated in italics to distinguish them from complement components. The values on the Y-axis represent the log2 ratios of the median levels calculated for the values extracted from independent references. The blue diamonds and light green triangles represent the log2 ratios of mRNA and protein levels in lung tissues, respectively. The red rectangles represent the log2 ratios of serum protein levels. The concentrations of 25 components (C1s, C1r, C1QA, C1QB, C2-C7, C8A, C8B, C1NH, CFI, C4BPA, CFH, CLU, SERPINA3, CD44, MRC1, APOA1, APOA2, APOC1, APOE and A2M) showed opposite trends: reduced mRNA and protein levels in lung cancer tissues but increased plasma protein levels in patients

Article Snippet: Antibodies against C5 (1:1000; ab66850), CFH (1:5000, ab36134) and C9 (1:1000, ab173302) were purchased from Abcam (Cambridge, MA); Antibodies against C4BPA (1:1000, 11,819–1-AP), C4BPB (1:1000, 15,837–1-AP), CFB (1:1000, 10,170–1-AP), and goat anti-rabbit, goat anti-mouse and rabbit anti-goat secondary antibodies were purchased from Proteintech Group, Inc., Wuhan Sanying (Wuhan, China).

Techniques: Expressing, Clinical Proteomics

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Bar plot showing fold-change expression of proteins identified in the secretome. B Bar plot showing protein levels of vimentin, EFEMP1 and C4BPA in FAPs secretome from healthy aged-matched controls ( n = 4) and DMD patients ( n = 6) analysed by ELISA. C Dot-plot showing EFEMP1 and C4BPA levels in serological samples from healthy aged-matched controls ( n = 16) and DMD patients ( n = 24) analysed by ELISA. Paired t-test was used to analyse. D Bar-plot showing the relative mRNA levels of C4BPA analysed in cells ( n = 2). E Western-blot results of C4BPA and GAPDH expression in muscle tissue from healthy controls ( n = 2) and DMD patients ( n = 2), and in FAP cells from healthy controls ( n = 3) and DMD patients ( n = 4). F Representative images of muscle histology from a healthy control young boy and a DMD patient stained with C4BPA, laminin and PDGFRα. Scale bar: 50 µm. and bar plot showing the area of C4BPA expressed in the IF tissue staining from healthy controls ( n = 3) and DMD patients ( n = 3). Data are shown as means ± SD; Results were statistically analysed using paired t-test analysis. Statistical significance was set at P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Western Blot, Control, Staining

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Timeline scheme of the differentiation of myoblasts with C4BPA treatment. B Bar plot showing the % area of myotubes and the ratio of nuclei/myotube of untreated and treated myoblasts with C4BPA after the differentiation process. C Myotube size graph and fiber size frequency in untreated and treated myoblasts with C4BPA after the differentiation process. D Bar plot showing the proliferation data after 24, 48 and 72 h. E Graphs showing different migratory parameters (mean-speed, median speed, total distance, linearity of forward progression and trajectory path of myoblasts after 72 h in culture. F Relative expression genes analysed after the differentiation process in non-treated and C4BPA-treated myoblasts. Data are represented as the mean of three replicates ± standard error of the mean. Results were statistically analysed using Mann-Whitney U. Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Expressing, MANN-WHITNEY

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Timeline scheme of the differentiation of the 3D culture with C4BPA treatment. B Representative cross-sectional image of a 3D muscle, untreated and treated with C4BPA. Staining corresponds to SAA, F-actinin and nuclei of tissues. C Bar graph showing myotube cross-section area (µm2) and Feret diameter (µm) after 10 days myoblasts differentiation with and without C4BPA treatment. D Bar graph showing the total number of myotubes measured per mm 2 or by tissue. E Bar graph showing contractile dynamics of the 3D muscle tissue after 10 days of differentiation. Twitch force (µN/mm2), tetanic force (µN/mm2), tetanic/twitch index, time in peak (seconds) and time to peak (seconds) parameters were measured. Data are shown as means ± SD; Statistical significance was set at P < 0.05, ** P < 0.01.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Staining

Journal: Cell Death & Disease

Article Title: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment

doi: 10.1038/s41419-026-08588-2

Figure Lengend Snippet: A Diagram scheme of the indirect co-culture of C4BPA siRNA-transfected FAPs with healthy myoblasts. B Relative expression of C4BPA mRNA levels after transfection ( n = 1). C Dot plot showing the differentiation index of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. D Dot plot showing the number of nuclei per myotube of myoblasts after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. E % of myotubes per field measured by MHCII staining after being co-cultured with transfected and non-transfected DMD FAPs and healthy FAPs. F Representative immunostaining of the indirect co-culture system analysed at the end of the differentiation process after FAPs transfection. Data are shown as means ± SD; Statistical significance was set at P < 0.05. ** P < 0.01; *** P < 0.001.

Article Snippet: The C4BPA siRNA, 5’-GCAAGUAGAGAUUAAGACAdTdT-3’ and MISSION® siRNA Universal Negative Control were synthesized by Merck Life Science.

Techniques: Co-Culture Assay, Transfection, Expressing, Cell Culture, Staining, Immunostaining